Vernalis PLC Announces Directorate Change

Vernalis plc (LSE: VER) announces today the forthcoming departure of Mr Tony Weir, Chief Financial Officer. He will be leaving on 14th November 2008 to join another company in the life sciences sector. Commenting, Peter Fellner, Chairman said:

“On behalf of the Board I would like to thank Tony for his considerable contribution as a key member of the management team over the past years. We wish him every success in his future career”.

The Company is in advanced discussions with potential successors, and expects to announce a new appointment shortly.

About Vernalis

Vernalis is an R&D-based pharmaceutical company with one marketed product, Frova®, six products in clinical development, and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec, Endo, Menarini and Chiesi.